(NASDAQ: EYPT) Eyepoint's forecast annual revenue growth rate of 225.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.93%.
Eyepoint's revenue in 2026 is $7,615,000.On average, 15 Wall Street analysts forecast EYPT's revenue for 2026 to be $169,443,263, with the lowest EYPT revenue forecast at $57,515,130, and the highest EYPT revenue forecast at $260,578,754. On average, 15 Wall Street analysts forecast EYPT's revenue for 2027 to be $3,322,295,275, with the lowest EYPT revenue forecast at $156,112,497, and the highest EYPT revenue forecast at $11,570,937,537.
In 2028, EYPT is forecast to generate $25,799,644,221 in revenue, with the lowest revenue forecast at $5,751,513,043 and the highest revenue forecast at $86,188,854,344.